ACO Models
Expert articles and analysis related to aco models.
AI Summary — Last 30 Days
ACO strategy is moving into a near-term fork-in-the-road moment as organizations accepted into CMS’s LEAD Model must finalize Participant TIN lists in early August while still awaiting final financial methodology—forcing many groups that also applied to MSSP to choose between models before fully knowing benchmark, payment, and downside-risk mechanics. This uncertainty is accelerating demand for actuarial risk mitigation, stop-loss coverage, and LEAD/MSSP scenario modeling, while conveners and infrastructure vendors position themselves as essential intermediaries for attribution, quality, data integration, and capital-light participation in downside risk arrangements (Wakely on LEAD next steps; Health Affairs on ACO conveners). At the same time, House movement to ease Medicare ACO quality reporting reflects
Related Articles
The LEAD model explained: A deep dive into the new ACO design
The LEAD model explained: A deep dive into the new ACO design Aledade
Medicare’s $35 Insulin Cap Lowered Beneficiary Costs, Increased Use for Some
The monthly spending limit improved adherence among insulin users who previously had especially high costs, Schaeffer researchers found. The post Medicare’s $35 Insulin Cap Lowered Beneficiary Costs, ...
340B claims data requirements put hospital discounts under stress
Provider advocates criticized Eli Lilly for ramping up pressure on hospitals to comply with a new policy regarding claims submission in the 340B Drug Pricing Program. The drug manufacturer said holdou...
TrumpRx Adds 160 More Drugs: Why the Latest Expansion Matters
TrumpRx Adds 160 More Drugs: Why the Latest Expansion Matters Pharmaceutical Commerce
OOP Insulin Cap Stabilizes Costs, Improves Adherence
With a $3.2m grant, rural hospitals may avoid generic drug shortages
The pilot program is starting in nine states.
Opinion: $2 million gene therapy cures require a financing model
“We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.
Insulin Cost Caps, Trade-Offs, and Pharmacoequity in Diabetes
Insulin Cost Caps, Trade-Offs, and Pharmacoequity in Diabetes JAMA
ADA 2026 Scientific Sessions: Increased Insulin Access After Medicare Cost Cap
Editorial: Insulin Cost Caps, Trade-offs, and Pharmacoequity in Diabetes ...
Brand Drugmakers Overcharge Americans while Lowering Prices Abroad
Brand Drugmakers Overcharge Americans while Lowering Prices Abroad AHIP